← All comparisons

Semaglutide vs GLP-3 R

Last updated

The key difference

Semaglutide is an approved GLP-1 receptor agonist. GLP-3 R is an investigational single molecule that activates the GLP-1, GIP, and glucagon receptors. GLP-3 R is not approved, and the two have been studied in separate trials rather than head to head.

Side by side

What it is
SemaglutideA long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
GLP-3 RGLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Research status
SemaglutideClinical
GLP-3 RClinical
Category
SemaglutideWeight & Metabolic
GLP-3 RWeight & Metabolic
Half-life
SemaglutideApproximately 7 days (once-weekly dosing)
GLP-3 RApproximately 6 days, supporting once-weekly dosing
Routes
Semaglutidesubcutaneous, oral
GLP-3 Rsubcutaneous
Reported dosing
SemaglutideClinical regimens titrate from 0.25 mg weekly up to 2.4 mg weekly (Wegovy) over several weeks to limit GI effects. Stated as labeled clinical dosing.
GLP-3 RResearch-use only and not medical advice; clinical trials escalated doses gradually up to roughly 12 mg subcutaneously once weekly, beginning at much lower starting doses to limit gastrointestinal effects.
Studied for
Semaglutide
  • Significant, sustained weight loss in clinical trials
  • Improves glycemic control in type 2 diabetes
  • Reduces cardiovascular events in high-risk patients
  • Increases satiety and reduces appetite
GLP-3 R
  • Produced large mean body-weight reductions in phase 2 trials
  • Triple agonism may raise energy expenditure via glucagon receptor
  • Improves glycemic control and HbA1c in type 2 diabetes studies
  • Reduces hepatic fat content relevant to fatty liver disease
Side effects
Semaglutide
  • Nausea, vomiting, and diarrhea (especially during titration)
  • Constipation and abdominal discomfort
  • Risk of pancreatitis (uncommon)
  • Gallbladder issues with rapid weight loss
GLP-3 R
  • Nausea, vomiting, and diarrhea, especially during dose escalation
  • Constipation and reduced appetite
  • Increased heart rate
  • Potential transient rise in fasting glucose at higher doses (glucagon effect)
Cited studies
Semaglutide5 on its page
GLP-3 R2 on its page

How Semaglutide works

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1, enhancing glucose-dependent insulin secretion and suppressing glucagon. It slows gastric emptying and acts on hypothalamic appetite centers to increase satiety and reduce food intake. Fatty-acid acylation extends its half-life to roughly one week, enabling once-weekly subcutaneous dosing.

Full Semaglutide profile →

How GLP-3 R works

GLP-3 R is a synthetic peptide that acts as a balanced agonist at three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). GLP-1R and GIPR agonism enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite via hypothalamic and brainstem circuits, while glucagon receptor agonism increases energy expenditure and hepatic lipid mobilization. The added glucagon component is thought to drive greater fat oxidation and metabolic rate compared with dual GLP-1/GIP agonists, producing larger reductions in body weight and hepatic fat in clinical trials.

Full GLP-3 R profile →

Dosing shown is what research and community sources report, not a recommendation. For educational and research purposes only; not medical advice. How we source this

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.